Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

Carmelo Gurnari; Alfonso Piciocchi; Stefano Soddu; Emilia Scalzulli; Pasquale Niscola; Ambra Di Veroli; Anna Lina Piccioni; Monica Piedimonte; Gianluca Maiorana; Prassede Salutari; Laura Cicconi; Michelina Santopietro; Svitlana Gumenyuk; Chiara Sarlo; Susanna Fenu; Agostino Tafuri; Roberto Latagliata; Luana Fianchi; Marianna Criscuolo; Jaroslaw P. Maciejewski; Luca Maurillo; Francesco Buccisano; Massimo Breccia; Maria Teresa Voso

doi:10.1038/s41408-022-00724-3

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Deletion of the long arm of chromosome 5, namely del(5q), is among the most recurrent cytogenetic aberrations in myelodysplastic syndromes (MDS), accounting for approximately 10–15% of all cases. Del(5q) defines a unique MDS sub-category, and represents the first genomic alteration included in the World Health Organization classification of MDS [ 1 ].

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gurnari et al. (2022) studied this question.

synapsesocial.com/papers/6a85211eaf90e4b27242e945 https://doi.org/10.1038/s41408-022-00724-3

View Full Paper

Ask AI

Bookmark

Share

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

Ask about this paper

Abstract

Discussion

Cite This Study

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading